SCHEDULE: Metsera Shareholders Receive $65.60 Cash Plus CVRs in Pfizer Merger

Metsera, Inc. has become a wholly-owned subsidiary of Pfizer Inc., with shareholders receiving $65.60 per share in cash and contingent value rights.

Summary

• Metsera, Inc. completed its merger with Pfizer Inc. on November 13, 2025, becoming a wholly-owned subsidiary of Pfizer.
• Each outstanding share of Metsera common stock was converted into the right to receive $65.60 in cash and one contractual contingent value right (CVR).
• The CVRs represent the right to receive additional contingent payments in cash upon the achievement of certain specified milestones.
• Population Health Partners, L.P., Population Health Partners GP, LLC, Christopher Whitten Bernard, Christopher T. Cox, and Clive A. Meanwell reported 0.0% beneficial ownership of Metsera common stock following the merger.
• This Schedule 13G Amendment No. 1 reflects the change in beneficial ownership by the reporting persons due to the merger and a prior internal share distribution.

Sentiment

Score: 7

Explanation: The filing confirms the successful completion of a merger, providing a clear exit for shareholders with a fixed cash payment and potential future upside via CVRs. While the company is no longer independent, the transaction itself is a positive resolution for its investors.

Positives

• Metsera shareholders received a fixed cash payment of $65.60 per share, providing immediate liquidity and a defined return.
• Shareholders also received contingent value rights, offering potential for additional payments based on future milestone achievements.
• The acquisition by Pfizer, a major pharmaceutical company, suggests a successful exit for Metsera and its investors.

Negatives

• Metsera, Inc. is no longer an independent publicly traded entity, removing its stock from public markets.
• The value of the contingent value rights is uncertain and dependent on future events and milestones.

Risks

• The value of the contingent value rights is subject to the achievement of specified milestones, which may not occur, or may occur later than anticipated.
• Shareholders no longer participate in the future growth or decline of Metsera as an independent company.

Future Outlook

The future outlook for former Metsera shareholders includes potential additional cash payments from contingent value rights, which are dependent on the achievement of specific milestones post-merger. Metsera itself is now a wholly-owned subsidiary of Pfizer Inc. and its future operations will be integrated within Pfizer.

Management Comments

• Each of PHP GP LLC, Christopher Whitten Bernard, Christopher T. Cox and Clive A. Meanwell disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that it is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

This acquisition by Pfizer Inc. of Metsera, Inc. reflects a continuing trend of consolidation within the pharmaceutical and biotechnology sectors, where larger established companies acquire innovative smaller firms to expand their pipelines, intellectual property, and market reach. The use of contingent value rights in the deal structure is also common in biotech acquisitions, allowing the acquirer to mitigate risk while providing upside potential to the acquired company's shareholders based on product development or regulatory milestones.

Comparison to Industry Standards

• The acquisition price of $65.60 per share, combined with CVRs, is a common structure in biotech M&A, similar to deals where upfront cash is supplemented by performance-based earn-outs.
• For example, in the acquisition of Arena Pharmaceuticals by Pfizer for $6.7 billion, shareholders received an all-cash consideration, while other deals like Bristol Myers Squibb's acquisition of MyoKardia included CVRs tied to specific drug approvals.
• The specific value of the CVRs would need to be assessed against similar contingent payment structures in other biotech acquisitions to determine if the potential upside is competitive.

Related Party Transactions

• Validae Health, L.P. distributed 99% of its Metsera shares to Population Health Partners, L.P. and 1% to Population Health Partners GP, LLC, which are related entities within the Population Health Partners group.

Stakeholder Impact

• Shareholders: Received $65.60 cash per share and contingent value rights, providing a defined return and potential future payments. They no longer hold shares in a publicly traded Metsera.
• Employees: Metsera employees are now part of Pfizer Inc., subject to integration plans.
• Customers/Suppliers: Operations will likely continue under Pfizer's ownership, potentially leading to changes in relationships over time.

Next Steps

• Monitoring the achievement of specified milestones for the contingent value rights to trigger potential future payments.
• Integration of Metsera's operations and assets into Pfizer Inc.

Key Dates

Keywords

Metsera Inc., Pfizer Inc., Merger, Acquisition, Contingent Value Rights, CVR, Schedule 13G, Common Stock, Pharmaceuticals, Biotech, Population Health Partners